Literature DB >> 15349875

Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia.

Hisanori Tomimitsu1, Kimiyoshi Arimura, Tatsui Nagado, Osamu Watanabe, Reika Otsuka, Asutsugu Kurono, Yoshito Sonoda, Mitsuhiro Osame, Masaki Kameyama.   

Abstract

Acquired neuromyotonia (ANM) is associated with antibodies to voltage-gated K+ channels (VGKCs). ANM sera reduce the number of K+ currents in neuronal cell lines, but it is not clear how the antibodies act. Here, we show by using the NB-1 cell line that the reduction in K+ currents by IgG is independent of added complement. IgG Fc and Fab fragments from ANM sera had no effect, but three of four ANM F(ab')2 fragments significantly reduced K+ currents. Thus, cross-linking of the channels by divalent antibodies is likely to be an important mechanism in reducing K+ currents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349875     DOI: 10.1002/ana.20221

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  Voltage-gated potassium channel complex antibodies in Creutzfeldt-Jakob disease.

Authors:  Koji Fujita; Tatsuhiko Yuasa; Osamu Watanabe; Yukitoshi Takahashi; Shuji Hashiguchi; Katsuhito Adachi; Yuishin Izumi; Ryuji Kaji
Journal:  J Neurol       Date:  2012-05-26       Impact factor: 4.849

2.  Antibody therapeutics targeting ion channels: are we there yet?

Authors:  Han Sun; Min Li
Journal:  Acta Pharmacol Sin       Date:  2013-02       Impact factor: 6.150

Review 3.  Autoimmune and paraneoplastic channelopathies.

Authors:  Steven Vernino
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

4.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.

Authors:  Sarosh R Irani; Sian Alexander; Patrick Waters; Kleopas A Kleopa; Philippa Pettingill; Luigi Zuliani; Elior Peles; Camilla Buckley; Bethan Lang; Angela Vincent
Journal:  Brain       Date:  2010-07-27       Impact factor: 13.501

5.  Autoimmune channelopathies of the nervous system.

Authors:  Kleopas A Kleopa
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

Review 6.  Ion channels as therapeutic antibody targets.

Authors:  Catherine J Hutchings; Paul Colussi; Theodore G Clark
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

Review 7.  Channelopathies.

Authors:  June-Bum Kim
Journal:  Korean J Pediatr       Date:  2014-01-31

8.  A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis.

Authors:  Han Sun; Liqun Luo; Bachchu Lal; Xinrong Ma; Lieping Chen; Christine L Hann; Amy M Fulton; Daniel J Leahy; John Laterra; Min Li
Journal:  Nat Commun       Date:  2016-02-04       Impact factor: 14.919

Review 9.  Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology.

Authors:  Bettina Balint; Angela Vincent; Hans-Michael Meinck; Sarosh R Irani; Kailash P Bhatia
Journal:  Brain       Date:  2018-01-01       Impact factor: 13.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.